XML 13 R2.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Current Assets:    
Cash and cash equivalents $ 132,953 $ 128,994
Marketable securities 217,617 213,591
Accounts receivable, net of reserves of $5,100 in 2016 and $5,128 in 2015 212,072 188,318
Inventories 183,759 188,833
Deferred income tax assets   39,829
Other current assets 62,605 62,069
Total current assets 809,006 821,634
Long-Term Assets:    
Property and equipment, net 343,010 333,026
Goodwill 181,941 178,934
Intangible assets, net 53,257 55,909
Other long-term assets 91,433 85,490
Total long-term assets 669,641 653,359
TOTAL ASSETS 1,478,647 1,474,993
Current Liabilities:    
Accounts payable 52,458 52,648
Accrued liabilities 178,267 205,530
Line of credit 622,000 573,000
Current portion of deferred revenue 25,943 25,583
Total current liabilities 878,668 856,761
Long-Term Liabilities:    
Deferred income tax liabilities 15,597 49,389
Long-term debt 600,021 597,085
Long-term deferred revenue, net of current portion 27,787 27,055
Other long-term liabilities 30,361 28,698
Total long-term liabilities 673,766 702,227
Total liabilities $ 1,552,434 $ 1,558,988
Commitments and Contingencies (Note 13)
Stockholders’ Deficit:    
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 102,546 and 102,237 shares in 2016 and 2015, respectively $ 10,255 $ 10,258
Additional paid-in capital 952,943 940,534
Deferred stock units: Outstanding: 240 units in both 2016 and 2015 5,432 5,409
Retained earnings 364,375 318,356
Accumulated other comprehensive loss (37,515) (42,265)
Treasury stock, at cost: 13,000 and 12,242 shares in 2016 and 2015, respectively (1,369,412) (1,316,417)
Total IDEXX Laboratories, Inc. stockholders’ deficit (73,922) (84,125)
Noncontrolling interest 135 130
Total stockholders’ deficit (73,787) (83,995)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $ 1,478,647 $ 1,474,993